tirzepatide sydney MOUNJARO® (tirzepatide) soon to be available for Australian adults with type 2 diabetes FDA approves tirzepatide, Eli Lilly's
Description
Bolded values refer to statistically significant findings
Furthermore, tirzepatides impact on body weight appears to be dose-dependent, with higher doses often resulting in more pronounced weight loss
The reduction in the BMI for those receiving tirzepatide and other incretin-based therapies is substantial but is not instantaneous
Recent advancements in diabetes treatment involve novel medications like GLP-1 receptor agonists and the newly approved tirzepatide.Tirzepatide is an innovative anti-diabetic medication that acts as a dual agonist for both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [9]
Change in waist and neck circumference
The medication is prescribed for adult patients who meet clinical criteria for chronic weight management
